Home » Topics » Science » New compound

New compound
RSS

Novel Nav1.7 channel inhibitor with potent analgesic activity in a mouse model of neuropathic pain

Dec. 4, 2020

Ashvattha Therapeutics presents htHD-FXRa for treating hepatic and biliary disorders

Dec. 2, 2020

A-3907 targets bile acid transport in the intestine and kidney for treating NASH, fibrosis

Dec. 2, 2020

New PDE4 inhibitor shows preclinical antifibrotic effect by inhibiting lung macrophage activity

Nov. 30, 2020

Early clinical data reported for [177Lu]rhPSMA-7.3 in mCRPC

Nov. 12, 2020

[64Cu]DOTA-UBI 29-41 for imaging of active infectious processes

Nov. 11, 2020

SARS-CoV-2 spike proteins directly activate the APC, which can be blocked by factor D inhibition

Nov. 9, 2020

[18F]AS3504073-00: a PET tracer for imaging mitochondrial fatty acid beta-oxidation in the heart

Nov. 6, 2020

First results for KSQ-4279 in treatment of BRCA-deficient cancers

Nov. 5, 2020

[68Ga]Desferal developed for imaging of bacterial infections

Nov. 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...